@article {Streeck2020.05.04.20090076, author = {Hendrik Streeck and Bianca Schulte and Beate M. K{\"u}mmerer and Enrico Richter and Tobias H{\"o}ller and Christine Fuhrmann and Eva Bartok and Ramona Dolscheid and Moritz Berger and Lukas Wessendorf and Monika Eschbach-Bludau and Angelika Kellings and Astrid Schwaiger and Martin Coenen and Per Hoffmann and Birgit Stoffel-Wagner and Markus M. N{\"o}then and Anna-Maria Eis-H{\"u}binger and Martin Exner and Ricarda Maria Schmithausen and Matthias Schmid and Gunther Hartmann}, title = {Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event}, elocation-id = {2020.05.04.20090076}, year = {2020}, doi = {10.1101/2020.05.04.20090076}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The world faces an unprecedented SARS-CoV2 pandemic where many critical factors still remain unknown. The case fatality rates (CFR) reported in the context of the SARS-CoV-2 pandemic substantially differ between countries. For SARS-CoV-2 infection with its broad clinical spectrum from asymptomatic to severe disease courses, the infection fatality rate (IFR) is the more reliable parameter to predict the consequences of the pandemic. Here we combined virus RT-PCR testing and assessment for SARS-CoV2 antibodies to determine the total number of individuals with SARS-CoV-2 infections in a given population.Methods A sero-epidemiological GCP- and GEP-compliant study was performed in a small German town which was exposed to a super-spreading event (carnival festivities) followed by strict social distancing measures causing a transient wave of infections. Questionnaire-based information and biomaterials were collected from a random, household-based study population within a seven-day period, six weeks after the outbreak. The number of present and past infections was determined by integrating results from anti-SARS-CoV-2 IgG analyses in blood, PCR testing for viral RNA in pharyngeal swabs and reported previous positive PCR tests.Results Of the 919 individuals with evaluable infection status (out of 1,007; 405 households) 15.5\% (95\% CI: [12.3\%; 19.0\%]) were infected. This is 5-fold higher than the number of officially reported cases for this community (3.1\%). Infection was associated with characteristic symptoms such as loss of smell and taste. 22.2\% of all infected individuals were asymptomatic. With the seven SARS-CoV-2-associated reported deaths the estimated IFR was 0.36\% [0.29\%; 0.45\%]. Age and sex were not found to be associated with the infection rate. Participation in carnival festivities increased both the infection rate (21.3\% vs. 9.5\%, p\<0.001) and the number of symptoms in the infected (estimated relative mean increase 1.6, p=0.007). The risk of a person being infected was not found to be associated with the number of study participants in the household this person lived in. The secondary infection risk for study participants living in the same household increased from 15.5\% to 43.6\%, to 35.5\% and to 18.3\% for households with two, three or four people respectively (p\<0.001).Conclusions While the number of infections in this high prevalence community is not representative for other parts of the world, the IFR calculated on the basis of the infection rate in this community can be utilized to estimate the percentage of infected based on the number of reported fatalities in other places with similar population characteristics. Whether the specific circumstances of a super-spreading event not only have an impact on the infection rate and number of symptoms but also on the IFR requires further investigation. The unexpectedly low secondary infection risk among persons living in the same household has important implications for measures installed to contain the SARS-CoV-2 virus pandemic.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00021306Funding StatementFunding: The government of the German Federal State of North Rhine-Westphalia unconditionally provided 65,000 Euro to support the study. No other financial support by any third parties was received or used for the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Medical Faculty of the University of Bonn (approval number 085/20) and has been registered at the German Clinical Trials Register (https://www.drks.de, identification number DRKS00021306). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available upon request}, URL = {https://www.medrxiv.org/content/early/2020/06/02/2020.05.04.20090076}, eprint = {https://www.medrxiv.org/content/early/2020/06/02/2020.05.04.20090076.full.pdf}, journal = {medRxiv} }